Physician profile
Simon Melnick
NPI 1093754780
$6,626.50
in general payments reported to CMS, 2019-2025
35 companies · $803 in 2025
The $803 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,282 · 2020: $548 · 2021: $37.61 · 2022: $660 · 2023: $1,116 · 2024: $1,180 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,138.72 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Allergan, INC. | $501.15 | 2019-2020 | |
| Amgen INC. | $443.97 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $392.22 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.86 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $341.27 | 2019 | |
| Pfizer INC. | $324.45 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $301.89 | 2022-2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $189.93 | 2019-2020 | |
| Exact Sciences Corporation | $170.39 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $155.26 | 2019-2022 | |
| Novo Nordisk INC | $134.50 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $132.76 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $126.50 | 2022-2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.46 | 2020-2025 | Xifaxan, Trulance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $78.19 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $74.64 | 2022-2024 | Quviviq |
| Abbvie INC. | $68.21 | 2021-2022 | |
| Abbott Laboratories | $63.68 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $61.34 | 2019-2023 | |
| Corcept Therapeutics | $59.37 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $58.63 | 2019-2023 | Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $50.00 | 2019-2020 | |
| Viatris Specialty LLC | $37.38 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $36.95 | 2019 | |
| Amarin Pharma, INC. | $30.21 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.59 | 2022 | |
| Scpharmaceuticals INC. | $21.68 | 2025 | |
| Nestle Healthcare Nutrition INC. | $21.18 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.47 | 2024 | Onpattro |
| Sanofi Pasteur INC. | $17.05 | 2019 | |
| Mylan Specialty L.P. | $16.06 | 2024 | Yupelri |
| Ironwood Pharmaceuticals, INC | $13.83 | 2019 | |
| Lupin INC. | $13.46 | 2019 | |
| Lucid Diagnostics INC. | $13.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Melnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.